Literature DB >> 25277324

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

Klazien W Matter-Walstra1, Rita Achermann, Roland Rapold, Dirk Klingbiel, Andrea Bordoni, Silvia Dehler, Gernot Jundt, Isabelle Konzelmann, Kerri Clough-Gorr, Thomas Szucs, Bernhard C Pestalozzi, Matthias Schwenkglenks.   

Abstract

The use of cancer-related therapies in cancer patients hospitalized at the end of life has increased in many countries over time. Given the scarcity of published Swiss data, the objective of this study was to evaluate the influence of hospital type and other factors on the delivery of health care during the last month before death. Claims data were used to assess health care utilization of cancer patients (identified by cancer registry data of four participating Swiss cantons) who deceased between 2006 and 2008. Primary endpoints were delivery of cancer-related therapies during the last 30 days before death. Multivariate logistic regression assessed the explanatory value of hospital type, patient and geographic characteristics. Of 3,809 identified cancer patients in the claims database, 2,086 patients dying from cancer were hospitalized during the last 30 days before death, generating 2,262 inpatient episodes. Anticancer drug therapy was given in 22.2% and radiotherapy in 11.7% of episodes. Besides age and cancer type, the canton of residence and hospital type showed independent, statistically significant associations with intensity of care, which was highest in university hospitals. These results should initiate a discussion among oncologists in Switzerland and may question the compliance with standard of care guidelines for terminal cancer patients.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25277324     DOI: 10.1159/000367629

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  The effect of a palliative care pathway on medical interventions at the end of life: a pre-post-implementation study.

Authors:  Annemieke van der Padt-Pruijsten; Maria B L Leys; Esther Oomen-de Hoop; Agnes van der Heide; Carin C D van der Rijt
Journal:  Support Care Cancer       Date:  2022-09-07       Impact factor: 3.359

Review 2.  Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review.

Authors:  Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton
Journal:  J Pain Symptom Manage       Date:  2019-10-19       Impact factor: 3.612

3.  Regional Variation of Cost of Care in the Last 12 Months of Life in Switzerland: Small-area Analysis Using Insurance Claims Data.

Authors:  Radoslaw Panczak; Xhyljeta Luta; Maud Maessen; Andreas E Stuck; Claudia Berlin; Kurt Schmidlin; Oliver Reich; Viktor von Wyl; David C Goodman; Matthias Egger; Marcel Zwahlen; Kerri M Clough-Gorr
Journal:  Med Care       Date:  2017-02       Impact factor: 2.983

4.  Intensity of treatment in Swiss cancer patients at the end-of-life.

Authors:  Caroline Bähler; Andri Signorell; Eva Blozik; Oliver Reich
Journal:  Cancer Manag Res       Date:  2018-03-15       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.